Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568301 | 0.86 | NPC1 (0.79) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL710016 | 0.81 | NPC1 (0.54) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL710015 | 0.81 | NPC1 (0.54) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL4876221 | 0.77 | CYP11B1 (0.57) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL4876228 | 0.77 | CYP11B1 (0.57) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL9778097 | 0.76 | NPC1 (0.73) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL13197417 | 0.76 | NPC1 (0.74) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL9268248 | 0.75 | CYP11B2 (1.00) | RAB9ANPC1KDM4ECYP11B1CYP11B2 | |
| SCHEMBL31668803 | 0.75 | CYP11B2 (1.00) | RAB9ANPC1KDM4ECYP11B1CYP11B2 | |
| SCHEMBL5496395 | 0.75 | CYP11B2 (1.00) | RAB9ANPC1KDM4ECYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | RAB9A 4723/4885NPC1 19/4885HPGD 1023/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | RAB9A 4606/4885NPC1 48/4885HPGD 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.